Alternatively released rewards, which were based on therapeutic effect Hollis (2005b) and to Pogge (2005) suggested an alternatively released reward system, in which a promotion agency would pay the rewards, on the drugs for neglected therapeutic effectiveness of the diseases 83 of the drugs for neglected diseases were annually based. The promotion agency would be a versatile financed body, like in the advanced obligation to take delivery request. In such enterprises with patented drugs would receive a cash reward to a system from the promoter, annually paid in some years, basedly on the therapeutic effectiveness of the drug, as of the promoter estimated. The enterprises, which accept the reward, were connected, to offer an opened license the drug in developing countries to manufacture and sell, but based on the total sales of the drug recompensed. This would make possible for generic competition to come in immediately created in such a way increase entrance to the drug, while enterprises were recompensed, on the individual property of the drug that each possible promoter is probable to evaluate: its effect on health. At the same time the pioneer an active interest was maintained, on, its drug to marked out, in order to increase consumption and therefore the number of units, on which it could be recompensed. An important part of this request is that it must be possible to measure the additional therapeutic effect of a new drug and the used quantity, with appropriate reliability. AsMaurer (2005) noticed, estimations of the therapeutic effect, usually measured inDALYs or quality-adjusted life years (QALYs), is really only approximate, and different method teachings can receive rather different estimations. However during such measures are incomplete, do not mean this that they cannot be used. If therapeutic value cannot be measured, how supervisory authorities decisions would meet on whether one makes marketing possible of the specific drugs? How would insurers decide whether one offers cover? Many national drug insurance offices, like in Australia, Canada and England, use express Kostengünstigkeitwerkzeuge, around decisions regarding, which drug is covered to meet (to see them Drummond, chapter 11). The technical problem of the determination of the size of the reward in a reward system is nearly identical to the problem of the insurer of the determination of the profitability of a given medicine (you see, chapter 10) to Pauly. Although some people have training objections to each possible estimation mechanism differently than the market, it is hard to see how this objection applies if the alternatively released reward systemis, since enterprises with objections continue to reward systemcould using the patent monopoly system exclusive. A problem with reward plans is generally that promoters confront an incentive to underestimate in order save innovations as way of money opportunistisch. In order to reduce the threat such opportunism, the alternatively released reward request requires the total cash rewards to be in advance regulated, if the portion of this reward is determined, each participation pioneer by the portion is paid the therapeutic use, which is zuzuschreibend innovations of this enterprise. Thus there is no way to reduce subsidy of the system. A problem with reward plan generally is that sponsor face innovation as A undervalue to incentive tons way OF opportunistically saving money. Ton reduce the threat OF look for opportunism, the optionally Reward proposal requires the totally cash rewards tons of fuel element fixed into advance, with the flock OF this reward paid tons each participating innovator determined by the flock OF the therapeutic benefit attributable tons that firm's innovation. Thus, there is NO way ton reduce payout OF the system.